This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | MicrobiomeTrials
← Back to trials NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-12-13Est. Completion: 2028-12
Enrollment target: 250 participantsLocations Yale Cancer Center, New Haven, Connecticut, United States University of Miami, Miami, Florida, United States Massachusetts General Hospital, Boston, Massachusetts, United States Dana Farber Cancer Institute, Boston, Massachusetts, United States Mayo Clinic, Rochester, Minnesota, United States Washington University, St Louis, Missouri, United States Mount Sinai, New York, New York, United States Cleveland Clinic, Cleveland, Ohio, United States Ohio State University, Columbus, Ohio, United States NEXT Oncology Austin, Austin, Texas, United States NEXT Oncology - Dallas, Irving, Texas, United States NEXT Oncology - San Antonio, San Antonio, Texas, United States Fred Hutchinson Cancer Center, Seattle, Washington, United States Princess Margaret, Toronto, Canada Institut Curie, Paris, France Institut Gustave Roussy, Villejuif, France Arensia Exploratory Medicine, Bucharest, Romania Arensia Exploratory Medicine, Cluj-Napoca, Romania Other microbiome trials you might be interested in Advanced Solid Tumor
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary …
Birmingham, United States Est. completion Nov 1, 2028
Non-Small Cell Lung Cancer (NSCLC)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who rece…
Santa Barbara, United States Est. completion Jun 30, 2027
Hospital Clinic Barcelona, Barcelona, Spain
Clinica Uni de Navara, Madrid, Spain Phase 1
Recruiting
Advanced Solid Tumor Locally Advanced Solid Tumor Metastatic Solid Tumor Platinum-resistant Ovarian Cancer Post Anti-PD-1 Melanoma 2L+ Cervical Cancer Neoadjuvant Melanoma Neoadjuvant Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Small Cell Lung Cancer Third Line or Later (3L+) HER2+ Breast Cancer Second or Third Line (2L/3L) Cervical Cancer Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Los Angeles, United States Est. completion Aug 2027